midodrine has been researched along with Hepatorenal Syndrome in 37 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
Hepatorenal Syndrome: Functional KIDNEY FAILURE in patients with liver disease, usually LIVER CIRRHOSIS or portal hypertension (HYPERTENSION, PORTAL), and in the absence of intrinsic renal disease or kidney abnormality. It is characterized by intense renal vasculature constriction, reduced renal blood flow, OLIGURIA, and sodium retention.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the beneficial and harmful effects of terlipressin versus other vasoactive drugs for people with hepatorenal syndrome." | 8.95 | Terlipressin versus other vasoactive drugs for hepatorenal syndrome. ( Allegretti, AS; Gluud, LL; Goldin, AH; Israelsen, M; Jovani, M; Krag, A; Winter, RW, 2017) |
| "Midodrine along with albumin infusion, is helpful in the secondary prophylaxis of HRS-AKI and reduces the number of ascites tap." | 8.02 | Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites. ( Arora, A; Bansal, N; Kumar, A; Puri, P; Sharma, P; ShriHari, AA; Singla, V, 2021) |
| "To analyse the impact of treatment with midodrine after hepatorenal syndrome type 2 reversal induced by terlipressin on the prevention of hepatorenal syndrome recurrence." | 7.75 | Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study. ( Alessandria, C; Carello, M; Ceretto, S; Debernardi-Venon, W; Marzano, A; Rizzetto, M, 2009) |
| " Midodrine and octreotide were dosed to obtain a stable increase of at least 15 mm Hg of mean arterial pressure." | 6.69 | Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. ( Amodio, P; Angeli, P; Caregaro, L; Craighero, R; Gatta, A; Gerunda, G; Maffei-Faccioli, A; Merenda, R; Roner, P; Sticca, A; Volpin, R, 1999) |
| "Terlipressin is an analog of the natural hormone arginine-vasopressin." | 6.44 | Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. ( Bendtsen, F; Borup, T; Krag, A; Møller, S, 2008) |
| "The adrenergic agonist midodrine improved circulatory and renal dysfunction when acutely administered in nonazotemic cirrhotic patients with ascites while its combination with octreotide has recently been proposed as an effective treatment of type 1 hepatorenal syndrome (HRS)." | 5.11 | The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. ( Al Bokharhii, J; Economou, M; Fotopoulos, A; Kalambokis, G; Katsaraki, A; Pappas, C; Tsianos, EV, 2005) |
| " We selected randomised controlled trials of adults (>18 years) with decompensated cirrhosis and type 1 hepatorenal syndrome that compared the efficacy of active vasoactive drugs (terlipressin, midodrine, octreotide, noradrenaline, and dopamine; alone or in combination) with placebo or each other." | 4.95 | Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. ( Chandar, AK; Facciorusso, A; Kamath, PS; Murad, MH; Muscatiello, N; Prokop, LJ; Singh, S, 2017) |
| "To evaluate the beneficial and harmful effects of terlipressin versus other vasoactive drugs for people with hepatorenal syndrome." | 4.95 | Terlipressin versus other vasoactive drugs for hepatorenal syndrome. ( Allegretti, AS; Gluud, LL; Goldin, AH; Israelsen, M; Jovani, M; Krag, A; Winter, RW, 2017) |
| "To review studies evaluating the use of midodrine and octreotide in hemodynamic complications of cirrhosis, including ascites and hepatorenal syndrome." | 4.85 | Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications. ( Karwa, R; Woodis, CB, 2009) |
| "Midodrine along with albumin infusion, is helpful in the secondary prophylaxis of HRS-AKI and reduces the number of ascites tap." | 4.02 | Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites. ( Arora, A; Bansal, N; Kumar, A; Puri, P; Sharma, P; ShriHari, AA; Singla, V, 2021) |
| "The combination of octreotide, midodrine, and albumin (triple therapy) is used to treat hepatorenal syndrome (HRS) often as a bridge to liver transplantation (LT)." | 3.77 | Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin. ( Rice, JP; Said, A; Skagen, C, 2011) |
| "To analyse the impact of treatment with midodrine after hepatorenal syndrome type 2 reversal induced by terlipressin on the prevention of hepatorenal syndrome recurrence." | 3.75 | Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study. ( Alessandria, C; Carello, M; Ceretto, S; Debernardi-Venon, W; Marzano, A; Rizzetto, M, 2009) |
| " Midodrine and octreotide were dosed to obtain a stable increase of at least 15 mm Hg of mean arterial pressure." | 2.69 | Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. ( Amodio, P; Angeli, P; Caregaro, L; Craighero, R; Gatta, A; Gerunda, G; Maffei-Faccioli, A; Merenda, R; Roner, P; Sticca, A; Volpin, R, 1999) |
| "Terlipressin plus albumin was more efficacious than placebo plus albumin (odds ratio=4." | 2.58 | Pharmacological Therapies for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis. ( Nanda, A; Reddy, R; Safraz, H; Salameh, H; Singal, AK, 2018) |
| " Future developments in dosage and administrative techniques for terlipressin may have an important role to play in maintaining clinical efficacy whilst improving tolerability in the management of HRS." | 2.58 | Hepatorenal syndrome: the clinical impact of vasoactive therapy. ( Colle, I; Laterre, PF, 2018) |
| "The hepatorenal syndrome is a well-recognized complication of advanced cirrhosis and is usually associated with an accelerated course to death unless liver transplantation is performed." | 2.53 | Emerging hepatic syndromes: pathophysiology, diagnosis and treatment. ( Bertino, G; Crisafulli, E; Demma, S; Koukias, N; Privitera, G; Purrello, F; Spadaro, L; Tsochatzis, EA, 2016) |
| "Terlipressin is an analog of the natural hormone arginine-vasopressin." | 2.44 | Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. ( Bendtsen, F; Borup, T; Krag, A; Møller, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.41) | 18.2507 |
| 2000's | 11 (29.73) | 29.6817 |
| 2010's | 19 (51.35) | 24.3611 |
| 2020's | 5 (13.51) | 2.80 |
| Authors | Studies |
|---|---|
| Bejjani, A | 1 |
| Zhang, Y | 1 |
| Behrens, A | 1 |
| Murray, B | 1 |
| Shah, N | 1 |
| Pitre, T | 1 |
| Kiflen, M | 1 |
| Helmeczi, W | 1 |
| Dionne, JC | 1 |
| Rewa, O | 1 |
| Bagshaw, SM | 1 |
| Needham-Nethercott, N | 1 |
| Alhazzani, W | 1 |
| Zeraatkar, D | 1 |
| Rochwerg, B | 1 |
| Thomson, MJ | 1 |
| Taylor, A | 1 |
| Sharma, P | 3 |
| Lok, AS | 1 |
| Tapper, EB | 1 |
| Hiruy, A | 1 |
| Nelson, J | 1 |
| Zori, A | 1 |
| Morelli, G | 1 |
| Cabrera, R | 1 |
| Kamel, A | 1 |
| Puri, P | 1 |
| Bansal, N | 1 |
| Singla, V | 1 |
| Kumar, A | 1 |
| ShriHari, AA | 1 |
| Arora, A | 1 |
| Facciorusso, A | 1 |
| Chandar, AK | 1 |
| Murad, MH | 1 |
| Prokop, LJ | 1 |
| Muscatiello, N | 1 |
| Kamath, PS | 2 |
| Singh, S | 1 |
| Israelsen, M | 1 |
| Krag, A | 2 |
| Allegretti, AS | 1 |
| Jovani, M | 1 |
| Goldin, AH | 1 |
| Winter, RW | 1 |
| Gluud, LL | 1 |
| Nanda, A | 1 |
| Reddy, R | 1 |
| Safraz, H | 1 |
| Salameh, H | 1 |
| Singal, AK | 1 |
| Kalambokis, GN | 2 |
| Baltayiannis, G | 1 |
| Christodoulou, D | 1 |
| Christou, L | 1 |
| Colle, I | 1 |
| Laterre, PF | 1 |
| Stine, JG | 1 |
| Wang, J | 1 |
| Cornella, SL | 1 |
| Behm, BW | 1 |
| Henry, Z | 1 |
| Shah, NL | 1 |
| Caldwell, SH | 1 |
| Northup, PG | 1 |
| Hsu, SJ | 1 |
| Huang, HC | 1 |
| Sourianarayanane, A | 1 |
| Raina, R | 1 |
| Garg, G | 1 |
| McCullough, AJ | 1 |
| O'Shea, RS | 1 |
| Maddukuri, G | 1 |
| Cai, CX | 1 |
| Munigala, S | 1 |
| Mohammadi, F | 1 |
| Zhang, Z | 1 |
| Cavallin, M | 1 |
| Merli, M | 1 |
| Fasolato, S | 1 |
| Toniutto, P | 1 |
| Salerno, F | 1 |
| Bernardi, M | 1 |
| Romanelli, RG | 1 |
| Colletta, C | 1 |
| Salinas, F | 1 |
| Di Giacomo, A | 1 |
| Ridola, L | 1 |
| Fornasiere, E | 1 |
| Caraceni, P | 1 |
| Morando, F | 1 |
| Piano, S | 1 |
| Gatta, A | 2 |
| Angeli, P | 2 |
| Graupera, I | 1 |
| Ginès, P | 2 |
| Velez, JC | 1 |
| Kadian, M | 1 |
| Taburyanskaya, M | 1 |
| Bohm, NM | 1 |
| Delay, TA | 1 |
| Karakala, N | 1 |
| Rockey, DC | 1 |
| Nietert, PJ | 1 |
| Goodwin, AJ | 1 |
| Whelan, TP | 1 |
| Glass, L | 1 |
| Salman, TA | 1 |
| Edrees, AM | 1 |
| El-Said, HH | 1 |
| El-Abd, OL | 1 |
| El-Azab, GI | 1 |
| Bertino, G | 1 |
| Privitera, G | 1 |
| Purrello, F | 1 |
| Demma, S | 1 |
| Crisafulli, E | 1 |
| Spadaro, L | 1 |
| Koukias, N | 1 |
| Tsochatzis, EA | 1 |
| Dong, T | 1 |
| Aronsohn, A | 1 |
| Gautham Reddy, K | 1 |
| Te, HS | 1 |
| Tsianos, EV | 2 |
| Borup, T | 1 |
| Møller, S | 1 |
| Bendtsen, F | 1 |
| Alessandria, C | 1 |
| Debernardi-Venon, W | 1 |
| Carello, M | 1 |
| Ceretto, S | 1 |
| Rizzetto, M | 1 |
| Marzano, A | 1 |
| Skagen, C | 2 |
| Einstein, M | 1 |
| Lucey, MR | 1 |
| Said, A | 2 |
| Karwa, R | 1 |
| Woodis, CB | 1 |
| Carl, DE | 1 |
| Sanyal, A | 1 |
| Rice, JP | 1 |
| Hasper, D | 1 |
| Jörres, A | 1 |
| Olivera-Martinez, M | 1 |
| Martinez, MO | 1 |
| Sayles, H | 1 |
| Vivekanandan, R | 1 |
| D' Souza, S | 1 |
| Florescu, MC | 1 |
| Wong, F | 1 |
| Pantea, L | 1 |
| Sniderman, K | 1 |
| Tong, W | 1 |
| Hurley, S | 1 |
| Hayashi, PH | 1 |
| Kalambokis, G | 1 |
| Economou, M | 1 |
| Fotopoulos, A | 1 |
| Al Bokharhii, J | 1 |
| Pappas, C | 1 |
| Katsaraki, A | 1 |
| Esrailian, E | 1 |
| Pantangco, ER | 1 |
| Kyulo, NL | 1 |
| Hu, KQ | 1 |
| Runyon, BA | 1 |
| Volpin, R | 1 |
| Gerunda, G | 1 |
| Craighero, R | 1 |
| Roner, P | 1 |
| Merenda, R | 1 |
| Amodio, P | 1 |
| Sticca, A | 1 |
| Caregaro, L | 1 |
| Maffei-Faccioli, A | 1 |
| Gerbes, AL | 1 |
| Gülberg, V | 1 |
| Ortega, R | 1 |
| Calahorra, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903): A Multicenter, Single-blind, Randomised Controlled Trial[NCT04028323] | Phase 4 | 60 participants (Anticipated) | Interventional | 2019-07-16 | Recruiting | ||
| A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Adaptive Dose-Ranging Study to Assess Safety and Efficacy of Intravenous OCE-205 in Adults Diagnosed With Cirrhosis With Ascites Who Have Developed Hepatorenal Syndrome-Acute Kidney Injury (HRS[NCT05309200] | Phase 2 | 47 participants (Actual) | Interventional | 2022-04-28 | Completed | ||
| Study on the Effect of Terlipressin on Recovery of Liver Function After Hepatectomy: a Multicenter Randomized Controlled Study[NCT04221672] | Phase 3 | 86 participants (Anticipated) | Interventional | 2019-11-07 | Recruiting | ||
| Rifaximin Prophylaxis Against Recurrence of Spontaneous Bacterial Peritonitis and Occurrence of Hepatorenal Syndrome in Decompensated Cirrhotic Egyptian Patients[NCT05621005] | Phase 2 | 104 participants (Actual) | Interventional | 2019-03-01 | Completed | ||
| Comparison of Endoscopic Band Ligation Plus 24-hour Versus 72-hour Terlipressin Therapy for the Control of Acute Variceal Bleeding in Patients With Liver Cirrhosis at a Tertiary Center in Mexico[NCT05331768] | 109 participants (Actual) | Interventional | 2021-01-01 | Completed | |||
| Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation[NCT00839358] | Phase 4 | 199 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Vasoconstrictors as Alternatives to Albumin After Large Volume Paracentesis in Cirrhosis[NCT00108355] | Phase 4 | 29 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Defined as an increase in Plasma Renin Activity (PRA) by >50% from baseline to a level > 4 ng/mL/h at post-paracentesis day (NCT00108355)
Timeframe: 6 days after paracentesis
| Intervention | participants (Number) |
|---|---|
| Albumin (Control Group) | 2 |
| Vasoconstrictor (Treatment Group) | 2 |
Comparison between Albumin (Control group) and Vasoconstrictor (Treatment group) (NCT00108355)
Timeframe: Variable depending on the patient, average 10 days
| Intervention | days (Median) |
|---|---|
| Albumin (Control Group) | 10 |
| Vasoconstrictor (Treatment Group) | 8 |
13 reviews available for midodrine and Hepatorenal Syndrome
| Article | Year |
|---|---|
The Comparative Effectiveness of Vasoactive Treatments for Hepatorenal Syndrome: A Systematic Review and Network Meta-Analysis.
Topics: Hepatorenal Syndrome; Humans; Midodrine; Network Meta-Analysis; Norepinephrine; Octreotide; Terlipre | 2022 |
Limited Progress in Hepatorenal Syndrome (HRS) Reversal and Survival 2002-2018: A Systematic Review and Meta-Analysis.
Topics: Adult; Albumins; Anti-Bacterial Agents; Dopamine; Drug Therapy, Combination; Female; Hepatorenal Syn | 2020 |
Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.
Topics: Dopamine; Drug Therapy, Combination; Gastrointestinal Agents; Hepatorenal Syndrome; Humans; Lypressi | 2017 |
Terlipressin versus other vasoactive drugs for hepatorenal syndrome.
Topics: Antihypertensive Agents; Dopamine; Hepatorenal Syndrome; Humans; Lypressin; Midodrine; Norepinephrin | 2017 |
Pharmacological Therapies for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis.
Topics: Albumins; Drug Therapy, Combination; Hepatorenal Syndrome; Humans; Infusions, Intravenous; Midodrine | 2018 |
Hepatorenal syndrome: the clinical impact of vasoactive therapy.
Topics: Biomarkers; Creatinine; Hepatorenal Syndrome; Humans; Lypressin; Midodrine; Norepinephrine; Octreoti | 2018 |
Management of ascites in patients with liver cirrhosis: recent evidence and controversies.
Topics: Ascites; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Midodrine; Portasystemic Shunt, T | 2013 |
Emerging hepatic syndromes: pathophysiology, diagnosis and treatment.
Topics: Acute Kidney Injury; Adrenal Insufficiency; Ascites; Creatinine; Evidence-Based Medicine; Hepatorena | 2016 |
Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hemodynamics; Hepatorenal Syndrome; Hum | 2008 |
Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications.
Topics: Ascites; Hemodynamics; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Midodrine; Octreotide; Treatme | 2009 |
The management of hepatorenal syndrome.
Topics: Albumins; Drug Therapy, Combination; Evidence-Based Medicine; Hepatorenal Syndrome; Humans; Liver Ci | 2009 |
New insights into the management of hepato-renal syndrome.
Topics: Disease Management; Hepatorenal Syndrome; Humans; Lypressin; Midodrine; Norepinephrine; Renal Dialys | 2011 |
[Vasoconstrictors in the treatment of hepatorenal syndrome].
Topics: Adrenergic alpha-Agonists; Albumins; Drug Evaluation; Drug Therapy, Combination; Hepatorenal Syndrom | 2002 |
7 trials available for midodrine and Hepatorenal Syndrome
| Article | Year |
|---|---|
Treatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical Trial.
Topics: Aged; Albumins; Drug Therapy, Combination; Female; Hepatorenal Syndrome; Hospital Mortality; Humans; | 2018 |
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
Topics: Aged; Albumins; Analysis of Variance; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatore | 2015 |
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
Topics: Aged; Albumins; Analysis of Variance; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatore | 2015 |
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
Topics: Aged; Albumins; Analysis of Variance; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatore | 2015 |
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
Topics: Aged; Albumins; Analysis of Variance; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatore | 2015 |
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
Topics: Aged; Albumins; Analysis of Variance; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatore | 2015 |
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
Topics: Aged; Albumins; Analysis of Variance; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatore | 2015 |
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
Topics: Aged; Albumins; Analysis of Variance; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatore | 2015 |
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
Topics: Aged; Albumins; Analysis of Variance; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatore | 2015 |
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
Topics: Aged; Albumins; Analysis of Variance; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatore | 2015 |
Effect of different therapeutic modalities on systemic, renal, and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis.
Topics: Adult; Bacterial Infections; Drug Therapy, Combination; Female; Hemodynamics; Hepatorenal Syndrome; | 2016 |
Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Topics: Adrenergic alpha-Agonists; Albumins; Aldosterone; Ascites; Blood Volume; Creatinine; Drug Therapy, C | 2004 |
The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Adult; Aged; Aldosterone; Blood Flow Velocity; Drug | 2005 |
Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
Topics: Aldosterone; Ascites; Blood Pressure; Diuresis; Electrolytes; Gastrointestinal Agents; Glomerular Fi | 1999 |
[Hepatorenal syndrome: a new therapeutic approach?].
Topics: Drug Therapy, Combination; Hepatorenal Syndrome; Humans; Kidney Function Tests; Midodrine; Octreotid | 1999 |
17 other studies available for midodrine and Hepatorenal Syndrome
| Article | Year |
|---|---|
Droxidopa in the Management of Hepatorenal Syndrome.
Topics: Droxidopa; Hepatorenal Syndrome; Humans; Male; Middle Aged; Midodrine; Norepinephrine; Octreotide | 2023 |
Standardized approach of albumin, midodrine and octreotide on hepatorenal syndrome treatment response rate.
Topics: Albumins; Drug Therapy, Combination; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Midodrine; Octre | 2021 |
Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites.
Topics: Acute Kidney Injury; Albumins; Ascites; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Midodrine; Pi | 2021 |
Terlipressin is superior to midodrine/octreotide for hepatorenal syndrome type 1.
Topics: Drug Therapy, Combination; Hepatorenal Syndrome; Humans; Lypressin; Midodrine; Octreotide; Retrospec | 2017 |
Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients.
Topics: Aged; Albumins; Female; Gastrointestinal Agents; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Live | 2014 |
Targeting an early and substantial increase in mean arterial pressure is critical in the management of type 1 hepatorenal syndrome: a combined retrospective and pilot study.
Topics: Albumins; Arterial Pressure; Disease Progression; Disease-Free Survival; Drug Therapy, Combination; | 2014 |
Hepatorenal syndrome: The last pieces of the puzzle or not yet?
Topics: Albumins; Female; Hepatorenal Syndrome; Humans; Lypressin; Male; Midodrine; Octreotide | 2015 |
Hepatorenal Acute Kidney Injury and the Importance of Raising Mean Arterial Pressure.
Topics: Acute Kidney Injury; Aged; Arterial Pressure; Creatinine; End Stage Liver Disease; Female; Hepatoren | 2015 |
Evidence-Based Therapeutic Options for Hepatorenal Syndrome.
Topics: Albumins; Female; Hepatorenal Syndrome; Humans; Lypressin; Male; Midodrine; Octreotide | 2016 |
Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis.
Topics: Acute Kidney Injury; Aged; Anti-Infective Agents; Case-Control Studies; End Stage Liver Disease; Fem | 2016 |
Vasoconstrictor therapy for patients with cirrhosis with ascites but without hepatorenal syndrome.
Topics: Adrenergic alpha-Agonists; Ascites; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Midodr | 2008 |
Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study.
Topics: Case-Control Studies; Drug Administration Schedule; Female; Hepatorenal Syndrome; Humans; Lypressin; | 2009 |
Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Albumins; Cohort Studies; Disease Progression; Drug Therapy, | 2009 |
Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin.
Topics: Adult; Albumins; Case-Control Studies; Chi-Square Distribution; Female; Glomerular Filtration Rate; | 2011 |
Hepatorenal syndrome: are we missing some prognostic factors?
Topics: Albumins; Alcoholism; Autoimmune Diseases; Creatinine; End Stage Liver Disease; Female; Hepatitis C; | 2012 |
Reconsidering hepatorenal syndrome. Throw in the towel? Not so fast!
Topics: Administration, Oral; Adult; Albumins; Creatinine; Drug Therapy, Combination; Fatal Outcome; Gastroi | 2004 |
Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome.
Topics: Creatinine; Drug Therapy, Combination; Female; Gastrointestinal Agents; Hepatorenal Syndrome; Humans | 2007 |